NASDAQ:SCYX SCYNEXIS (SCYX) Stock Price, News & Analysis $2.86 +0.01 (+0.35%) As of 12:28 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About SCYNEXIS Stock (NASDAQ:SCYX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SCYNEXIS alerts:Sign Up Key Stats Today's Range$2.70▼$2.9350-Day Range$2.85▼$5.3752-Week Range$2.70▼$9.12Volume48,137 shsAverage Volume130,315 shsMarket Capitalization$28.46 millionP/E RatioN/ADividend YieldN/APrice Target$33.00Consensus RatingHold Company Overview SCYNEXIS, Inc. is a biotechnology company focused on developing antifungal medicines for infections that can be difficult to treat. Its research has centered on ibrexafungerp, an antifungal from the triterpenoid class that works through a mechanism distinct from that of commonly used azole antifungals. Ibrexafungerp was approved by the U.S. Food and Drug Administration as Brexafemme for treating vulvovaginal candidiasis and later for reducing recurrent episodes of the condition. SCYNEXIS licensed rights to the drug to GSK under an agreement covering its development and commercialization. The company’s work has also included exploring ibrexafungerp for other fungal infections, including serious invasive infections. Its regulatory history and commercial relationships have been centered primarily on the United States; SCYNEXIS has not been described here as having a broad direct-sales presence.AI Generated. May Contain Errors. Read More SCYNEXIS Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreSCYX MarketRank™: 2.33968804159 of 5 starsSCYNEXIS scored higher than 47% of companies evaluated by MarketBeat, and ranked 582nd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingSCYNEXIS has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSCYNEXIS has a consensus price target of $33.00, representing about 1,057.9% upside from its current price of $2.85.Amount of Analyst CoverageSCYNEXIS has only been the subject of 1 research reports in the past 90 days.Read more about SCYNEXIS's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SCYNEXIS are expected to grow in the coming year, from ($3.48) to ($0.37) per share.Price to Book Value per Share RatioSCYNEXIS has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.72% of the float of SCYNEXIS has been sold short.Short Interest Ratio / Days to CoverSCYNEXIS has a short interest ratio ("days to cover") of 5.55.Change versus previous monthShort interest in SCYNEXIS has recently increased by 7.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSCYNEXIS does not currently pay a dividend.Dividend GrowthSCYNEXIS does not have a long track record of dividend growth. News and Social Media2.1 / 5News SentimentN/A News SentimentSCYNEXIS has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for SCYNEXIS this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added SCYNEXIS to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, SCYNEXIS insiders have not sold or bought any company stock.Percentage Held by Insiders4.09% of the stock of SCYNEXIS is held by insiders.Percentage Held by Institutions54.37% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about SCYNEXIS's insider trading history. Receive SCYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SCYX Stock News HeadlinesFY2026 EPS Forecast for SCYNEXIS Reduced by AnalystNovember 12, 2026 | americanbankingnews.comSCYNEXIS Targets Year-End Kidney Drug Trial as Antifungal Program AdvancesNovember 10, 2026 | americanbankingnews.comWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 18 at 1:00 AM | Porter & Company (Ad)SCYNEXIS (NASDAQ:SCYX) Cut to "Sell" at Wall Street ZenNovember 10, 2026 | americanbankingnews.comSCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 5, 2026 | globenewswire.comSCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation ConferenceOctober 29, 2026 | globenewswire.comSCYNEXIS: IV SCY-247 Shows Favorable Safety And Exposure In Phase 1 StudyOctober 22, 2026 | rttnews.comSCYNEXIS Secures Up To $214M In BARDA Support For SCY-247 Development; Stock UpOctober 22, 2026 | rttnews.comSee More Headlines SCYX Stock Analysis - Frequently Asked Questions How have SCYX shares performed this year? SCYNEXIS's stock was trading at $5.0592 at the start of the year. Since then, SCYX shares have decreased by 43.7% and is now trading at $2.85. How were SCYNEXIS's earnings last quarter? SCYNEXIS, Inc. (NASDAQ:SCYX) released its quarterly earnings results on Thursday, November, 5th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.72) by $0.01. The firm earned $130 thousand during the quarter, compared to analysts' expectations of $130 thousand. When did SCYNEXIS's stock split? Shares of SCYNEXIS reverse split before market open on Monday, June 1st 2026.The 1-8 reverse split was announced on Friday, May 22nd 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 29th 2026. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did SCYNEXIS IPO? SCYNEXIS (SCYX) raised $62 million in an IPO on Thursday, April 3rd 2014. The company issued 6,200,000 shares at a price of $10.00 per share. Who are SCYNEXIS's major shareholders? Top institutional investors of SCYNEXIS include Great Point Partners LLC (9.49%). View institutional ownership trends. How do I buy shares of SCYNEXIS? Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SCYNEXIS own? Based on aggregate information from My MarketBeat watchlists, some other companies that SCYNEXIS investors own include Advanced Micro Devices (AMD), Tesla (TSLA), Matinas Biopharma (MTNB), NVIDIA (NVDA), Micron Technology (MU), Viking Therapeutics (VKTX) and NIO (NIO). Company Calendar Last Earnings11/05/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SCYX's financial health is in the Red zone, according to TradeSmith. SCYX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SCYX CIK1178253 Webwww.scynexis.com Phone(201) 884-5485Fax201-884-5490Employees29Year Founded2000Price Target and Rating Average Price Target for SCYNEXIS$33.00 High Price Target$33.00 Low Price Target$33.00 Potential Upside/Downside+1,053.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.61 million Net MarginsN/A Pretax Margin-53.50% Return on Equity-39.29% Return on Assets-30.45% Debt Debt-to-Equity RatioN/A Current Ratio7.57 Quick Ratio7.57 Sales & Book Value Annual Sales$20.60 million Price / Sales1.38 Cash FlowN/A Price / Cash FlowN/A Book Value$5.93 per share Price / Book0.48Miscellaneous Outstanding Shares9,950,000Free Float9,546,000Market Cap$28.47 million OptionableOptionable Beta1.15 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:SCYX) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersGold Trades Near Record Highs: What It Means for MinersBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredEarn $4,500 a month? Your income may count for moreEarn $4,500 or more a month? Pennie lets you explore personal loan options that consider your income, not just...Pennie Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.